These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24435447)

  • 21. Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis.
    Wen ZH; Su YC; Lai PL; Zhang Y; Xu YF; Zhao A; Yao GY; Jia CH; Lin J; Xu S; Wang L; Wang XK; Liu AL; Jiang Y; Dai YF; Bai XC
    Oncogene; 2013 Jan; 32(2):160-70. PubMed ID: 22349822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulated in DNA damage and development 1 (REDD1) promotes cell survival during serum deprivation by sustaining repression of signaling through the mechanistic target of rapamycin in complex 1 (mTORC1).
    Dennis MD; McGhee NK; Jefferson LS; Kimball SR
    Cell Signal; 2013 Dec; 25(12):2709-16. PubMed ID: 24018049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway.
    Gen Y; Yasui K; Nishikawa T; Yoshikawa T
    Cancer Sci; 2013 Jul; 104(7):810-6. PubMed ID: 23510069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-metabolic functions of glycolytic enzymes in tumorigenesis.
    Yu X; Li S
    Oncogene; 2017 May; 36(19):2629-2636. PubMed ID: 27797379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
    Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
    Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. mTOR Inhibition Restores Amino Acid Balance in Cells Dependent on Catabolism of Extracellular Protein.
    Nofal M; Zhang K; Han S; Rabinowitz JD
    Mol Cell; 2017 Sep; 67(6):936-946.e5. PubMed ID: 28918901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer.
    Wang C; Cigliano A; Delogu S; Armbruster J; Dombrowski F; Evert M; Chen X; Calvisi DF
    Cell Cycle; 2013 Jul; 12(13):1999-2010. PubMed ID: 23759595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amino acids and mTORC1: from lysosomes to disease.
    Efeyan A; Zoncu R; Sabatini DM
    Trends Mol Med; 2012 Sep; 18(9):524-33. PubMed ID: 22749019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oleate-mediated activation of phospholipase D and mammalian target of rapamycin (mTOR) regulates proliferation and rapamycin sensitivity of hepatocarcinoma cells.
    Arous C; Naïmi M; Van Obberghen E
    Diabetologia; 2011 Apr; 54(4):954-64. PubMed ID: 21240477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Key mediators of intracellular amino acids signaling to mTORC1 activation.
    Duan Y; Li F; Tan K; Liu H; Li Y; Liu Y; Kong X; Tang Y; Wu G; Yin Y
    Amino Acids; 2015 May; 47(5):857-67. PubMed ID: 25701492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The expanding role of mTOR in cancer cell growth and proliferation.
    Cargnello M; Tcherkezian J; Roux PP
    Mutagenesis; 2015 Mar; 30(2):169-76. PubMed ID: 25688110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
    Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
    Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells.
    Le Gendre O; Sookdeo A; Duliepre SA; Utter M; Frias M; Foster DA
    Mol Cancer Res; 2013 May; 11(5):474-81. PubMed ID: 23443316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glutaminolysis feeds mTORC1.
    Durán RV; Hall MN
    Cell Cycle; 2012 Nov; 11(22):4107-8. PubMed ID: 23095634
    [No Abstract]   [Full Text] [Related]  

  • 36. Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors.
    Faes S; Duval AP; Planche A; Uldry E; Santoro T; Pythoud C; Stehle JC; Horlbeck J; Letovanec I; Riggi N; Demartines N; Dormond O
    Mol Cancer; 2016 Dec; 15(1):78. PubMed ID: 27919264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re-evaluating the roles of proposed modulators of mammalian target of rapamycin complex 1 (mTORC1) signaling.
    Wang X; Fonseca BD; Tang H; Liu R; Elia A; Clemens MJ; Bommer UA; Proud CG
    J Biol Chem; 2008 Nov; 283(45):30482-92. PubMed ID: 18676370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapamycin treatment improves neuron viability in an in vitro model of stroke.
    Fletcher L; Evans TM; Watts LT; Jimenez DF; Digicaylioglu M
    PLoS One; 2013; 8(7):e68281. PubMed ID: 23861877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
    Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
    Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet-derived growth factor regulates vascular smooth muscle phenotype via mammalian target of rapamycin complex 1.
    Ha JM; Yun SJ; Kim YW; Jin SY; Lee HS; Song SH; Shin HK; Bae SS
    Biochem Biophys Res Commun; 2015 Aug; 464(1):57-62. PubMed ID: 26032503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.